-
EP3841097
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3841097
| EP3841097 - 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 16.12.2022 Database last updated on 03.09.2024 | |
| Former | Request for examination was made Status updated on 28.05.2021 | ||
| Former | The international publication has been made Status updated on 28.02.2020 | ||
| Former | unknown Status updated on 13.09.2019 | Most recent event Tooltip | 05.06.2024 | New entry: Despatch of examination report + time limit | Applicant(s) | For all designated states Biomedical Research Foundation of the Academy of Athens Soranou Efesiou Str. 4 115 27 Athens / GR | For all designated states Agricultural University of Athens (AUA) Iera Odos 75 1185 Athens / GR | For all designated states Foundation for Research and Technology - Hellas (Forth) N. Plastira 100 713 Heraklion, Crete / GR | For all designated states Cournia, Zoe Nileos 8B 14564 Kifissia / GR | For all designated states Efstratiadis, Argiris Kleomenous 37-39 10676 Athens / GR | For all designated states Kapella, Anna Eleftherias 56 16346 Ilioupoli / GR | For all designated states Couladouros, Elias 28th October 37 15451 Neo Psichico / GR | [2021/26] | Inventor(s) | 01 /
CHRISTOFORIDIS, Savvas N.Plastira 100 713 Heraklion, Crete / GR | 02 /
COURNIA, Zoe Nileos 8B 14564 Kifissia / GR | 03 /
EFSTRATIADIS, Argiris Kleomenous 37-39 10676 Athens / GR | 04 /
KAPELLA, Anna Eleftherias 56 16346 Ilioupoli / GR | 05 /
COULADOUROS, Elias 28th October 37 15451 Neo Psichico / GR | [2021/26] | Representative(s) | Weickmann & Weickmann PartmbB Postfach 860 820 81635 München / DE | [N/P] |
| Former [2021/26] | Böhm, Brigitte, et al Weickmann & Weickmann Patent- und Rechtsanwälte PartmbB Postfach 860 820 81635 München / DE | Application number, filing date | 19762730.0 | 23.08.2019 | [2021/26] | WO2019EP72648 | Priority number, date | GR20180102981 | 24.08.2018 Original published format: GR 20180102981 | [2021/26] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020039097 | Date: | 27.02.2020 | Language: | EN | [2020/09] | Type: | A1 Application with search report | No.: | EP3841097 | Date: | 30.06.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 27.02.2020 takes the place of the publication of the European patent application. | [2021/26] | Search report(s) | International search report - published on: | EP | 27.02.2020 | Classification | IPC: | C07D401/14, C07D213/81, A61K31/4439, A61P35/00 | [2021/26] | CPC: |
C07D401/14 (EP,US);
A61K45/06 (US);
A61P35/00 (EP);
C07D213/81 (EP);
C07D213/90 (US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/26] | Title | German: | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDIN UND N2,N6-DIBENZYLPYRIDIN-2,6-DICARBOXAMIDDERIVATE UND VERWANDTE VERBINDUNGEN ALS PHOSPHOINOSITID-3-KINASE(PI3K)-INHIBITOREN ZUR BEHANDLUNG VON KREBS | [2021/26] | English: | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | [2021/26] | French: | DÉRIVÉS DE 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)MÉTHYL)PYRIDINE ET DE N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE ET COMPOSÉS ASSOCIÉS EN TANT QU'INHIBITEURS DE PHOSPHOINOSITIDE 3-KINASE (PI3K) DANS LE TRAITEMENT DU CANCER | [2021/26] | Entry into regional phase | 19.03.2021 | National basic fee paid | 19.03.2021 | Designation fee(s) paid | 19.03.2021 | Examination fee paid | Examination procedure | 19.03.2021 | Examination requested [2021/26] | 19.03.2021 | Date on which the examining division has become responsible | 21.10.2021 | Amendment by applicant (claims and/or description) | 16.12.2022 | Despatch of a communication from the examining division (Time limit: M06) | 26.06.2023 | Reply to a communication from the examining division | 26.09.2023 | Despatch of a communication from the examining division (Time limit: M04) | 26.01.2024 | Reply to a communication from the examining division | 04.06.2024 | Despatch of a communication from the examining division (Time limit: M04) | Fees paid | Renewal fee | 28.10.2021 | Renewal fee patent year 03 | 31.08.2022 | Renewal fee patent year 04 | 31.07.2023 | Renewal fee patent year 05 | Penalty fee | Additional fee for renewal fee | 31.08.2021 | 03 M06 Fee paid on 28.10.2021 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XAI]US2003199560 (YONETANI YOSHIYUKI [JP], et al); | [XAI]WO2004072027 (AVENTIS PHARMA SA [FR], et al); | [XA]US2005255415 (LOUWET FRANK [BE], et al); | [XA]WO2014110476 (EINSTEIN COLL MED [US]); | [XAI]WO2015048547 (RIGEL PHARMACEUTICALS INC [US], et al); | [XAI]KR20150066786 (UNIV ULSAN FOUND FOR IND COOP [KR]); | [XAI]KR20160011727 (UNIV ULSAN FOUND FOR IND COOP [KR]); | [A]WO2018057810 (GILEAD SCIENCES INC [US]); |